M

Mass General Brigham

Early-stage life science venture investor

Certified Nursing Assistant

Part-Time
$22 - $32.69/hr+ Differentials + Premiums + Bonuses
Entry
Jamaica Plain, Boston, MA, USA
In Person
Medical, Clinical & VeterinaryNursing & Frontline Patient Care

About the job

Requirements
  • A high school diploma or equivalent is required.
  • A Certified Nursing Assistant/Patient Care Technician credential and HeartSaver CPR AED certification from the American Heart Association are required.
  • Successful completion of an approved nursing assistant training program.
  • Ability to effectively speak, read, and write English.
  • Ability to pass clinical competency, basic math, and reading testing.
  • Ability to perform basic math calculations and measurements, including measuring height and weight, intake and output, and calorie counts.
  • Ability to accurately interpret and use basic medical terminology and abbreviations.
  • Ability to enter and retrieve computerized information.
  • Physical ability to push, transfer, and pull heavy loads throughout the assigned shift.
  • Physical ability to meet core job requirements in accordance with practice-setting demands and the patient populations regularly served.
  • Interpersonal skills to interact appropriately with nursing staff, patients, families and visitors, physicians, and other hospital staff.
  • Organizational skills to set priorities and efficiently complete assigned work.
  • Ability to manage stress related to patient care issues and a changing hospital climate and personnel issues.
  • Staff must adhere to all I C.A.R.E. Standards.
Responsibilities
  • Assist in maintaining a safe environment, intervene appropriately, and identify or initiate appropriate follow-up for safety issues.
  • Use judgment when implementing physician orders and notify the charge nurse immediately of concerns.
  • Ensure patient and family needs and expectations are met in a timely and caring manner, maintaining C.A.R.E. standards focused on communication, appearance, and respect.
  • Work collaboratively on the Patient Care Team and proactively support smooth and efficient unit operations.
  • Maintain and promote the organization’s mission and values, maintain confidentiality of patient information, and respect and support a culturally diverse staff and patient population.
  • Address patient or family concerns using proper procedures and notify the Nursing Director, supervisor, or clinical leader.
  • Order, expedite, and distribute unit, clerical, and patient-care supplies as directed; order unit supplies through eBUY, including Workflow One, and maintain required par levels.
  • Keep the work area and office equipment neat and functioning; initiate and track Facilities, Biomed, Housekeeping, and IT problems, replacements, requests, and work orders.
  • Notify Biomed of malfunctioning equipment, arrange repair requests, and coordinate equipment return to the department.
  • Assist the Nursing Director with unit projects and liaise with ancillary services and other departments to solve problems affecting unit activities.
  • Provide backup patient-transport coverage, including escorting discharged patients and families.
  • Answer, coordinate, and manage unit phone calls in consultation with the charge nurse; take accurate messages and deliver them promptly, and place pages and calls at clinical staff’s request.
  • Participate in shift handoffs by giving or receiving reports with the incoming or outgoing unit secretary and charge RN.
  • Coordinate notifications to appropriate staff about paperwork received on the unit, including fax referrals.
  • Maintain patient medical records according to hospital policy, label pages, and file test results and other information accurately and promptly.
  • Schedule patient diagnostic tests, appointments, and consultations as directed by a physician or RN.
  • Coordinate patient discharge logistics, including transportation and equipment.
  • Complete clerical admission, transfer, and discharge tasks using the bed-management system; ensure patient records, information plates or labels, belongings, and other pertinent information accompany patients during transfers.
  • Enter, update, or print data reports as appropriate, including bed-management activity, diet-order sheets, advance care directives and code status, medication reconciliation and restraint reports, Quadramed assignment sheets, and recovery charges or billing information.
  • Check the Quadramed list by 11:30 a.m., notify the charge nurse of unclassified inpatients, and remind staff to complete their Quadrameds.
  • Copy patient charts and other materials as requested.
  • Use Meditech to access and update administrative data screens, enter transport requests and PASSPORT orders, and print specimen labels, kardexes, and medication administration reports.
  • Request and maintain old medical records as needed.
  • Anticipate discharges and transfers; notify admitting or the nursing supervisor when known and enter tentative discharges in the bed-management system.
  • Update the charge nurse or clinical leader, admitting, and nursing supervisor about admissions, discharges, and transfers on applicable shifts, and enter tentative discharges in the bed-management system.
  • Communicate with healthcare team members using the VOCERA communication device.
  • Perform other assigned duties.
  • Interact with healthcare team members to provide interdisciplinary, patient- and family-centered care; answer patient call lights and communicate requests to appropriate clinical staff.
  • Provide clerical support to unit staff and float to other pods or units as requested by the Nursing Office.
  • Receive and orient visitors professionally, projecting a positive public image through C.A.R.E. standards, and provide patients and families with basic information about unit operations.
  • Maintain compliance with hospital and unit-secretary competencies; seek unit- or service-related continuing education.
  • Orient or precept new personnel as assigned and act as a resource for professionals, patients, and significant others on the unit.
  • Respond to healthcare-team staffing needs by cross-training and floating to other units.
  • Attend staff meetings or review meeting minutes to stay current on unit and organizational updates; attend the annual Safety Fair.
  • Understand unit-specific quality indicators and participate in Quality Improvement projects and committees as directed by the Nursing Director, including Service, Excellence, and Quality programs such as the Falls Team, Patient Safety Committee, and Pain Management Team.
  • Respond to patient and family needs by answering call lights and telephone calls promptly, and coordinate patient communication through general reception and clerical duties.

About the company

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Mass General Brigham reported $15 million operating income through June 30, 2026.
  • Outpatient growth and higher-acuity inpatient volumes drove 7% revenue growth in Q3 FY26.
  • Abcuro's 2026 financing extends a potential registrational trial, validating MGB Ventures sourcing.

What critics are saying

  • Brigham nurses authorized an indefinite strike on September 24, 2026; operations face disruption.
  • MGB refused negotiations after July strikes and lockouts, deepening staffing instability into 2027.
  • The September 2026 antidiscrimination case and website-data settlement reinforce litigation overhangs.

What makes Mass General Brigham unique

  • Mass General Brigham controls flagship Boston hospitals and a research-to-venture pipeline.
  • MGB Ventures backed Abcuro's $66 million Series D in August 2026.
  • Its $22.8 billion 2025 operating revenue funds clinical, academic, and commercialization depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • Flexible Work Hours
  • Remote Work Options
  • Hybrid Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Family Planning Benefits
  • Fertility Treatment Support

Company News

Business Wire
Oct 25th, 2026
Nocion Therapeutics Extends Series B Financing to $93 Million to Support Late-Stage Development of Taplucainium in Chronic Cough

Nocion Therapeutics, Inc. today announced that it has raised $23 million from existing investors in an extension of its Series B, bringing the total amount o...

PR Newswire
Oct 1st, 2026
Mass General Brigham postpones annual summit after nurses plan picket over $2.3B hospital system refusing fair contracts

Mass General Brigham has postponed its annual summit after nurses and clinicians represented by the Massachusetts Nurses Association issued a picket notice for the 7 October event in Somerville. The postponement follows a 93% strike authorisation vote by Brigham and Women's Hospital nurses and protests against MGB executives. MGB nurses and clinicians have been campaigning against the hospital system following strikes and a lockout in July. Brigham nurses are seeking contract improvements including limits on temporary nurses, affordable health insurance, and fair compensation. MGB Home Care clinicians are negotiating their first union contract. MGB reported $22.8 billion in operating revenue and $2.39 billion in profits for fiscal year 2025. The system has refused to return to negotiations since August.

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.